What are German insurers’ latest reimbursement tactics, and how are pharmas responding with novel deals of their own?
What lessons do moves by players including Novartis, Pfizer, Wyeth, Sanofi-Aventis and Novo Nordisk bring to the U.S. in the era of health care reform? What could be the impact of similar trends emerging in the U.S.?
Join us for a can’t-miss webinar on Thursday, Oct 8, at 11 AM EST/5 PM CET with a panel of experts who will help answer these questions, and analyze how the evolution of rebate deals in Germany may provide clues as to what flavors of reimbursement trend may appear elsewhere.
For more information, click: http://www.windhover.com/ezine/html/ac1009-2lp.htm
